Biogen's Alzheimer's drug Aduhelm faces EU rejection

Biogen hasn't won support to have its Alzheimer's treatment Aduhelm marketed in the EU, as the drug has received a negative opinion in a trend vote from the EMA's expert committee, the CHMP. The formal rejection of Biogen's marketing authorization application is expected in December.

Photo: POOL New/VIA REUTERS / X80003

The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs